Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 134 publications
Retraction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.
Journal: The Journal of experimental medicine
Published: June 30, 2026
Accuracy of Real-Time PK-Guided Melphalan Dosing in Achieving Target Exposure in Myeloma Patients Undergoing Autologous Transplant.
Journal: Pharmaceutics
Published: May 21, 2026
The Evolution of Chimeric Antigen Receptor T-Cell, Bispecific Antibodies and Antibody-Drug Conjugates for the Treatment of Multiple Myeloma.
Journal: Clinical lymphoma, myeloma & leukemia
Published: February 06, 2026
Early CD4+ T cell proliferation and chronic T cell engagement impact myeloma outcomes following T cell engager therapy.
Journal: The Journal of clinical investigation
Published: August 05, 2025
Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience.
Journal: Haematologica
Published: May 21, 2025
Feasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract.
Journal: Clinical lymphoma, myeloma & leukemia
Published: February 21, 2025
Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at 2 Institutes.
Journal: Clinical lymphoma, myeloma & leukemia
Published: January 07, 2025
Immune-aging is linked to clinical malignancy, racial ancestry, and vaccine responses in myeloma.
Journal: Blood advances
Published: December 20, 2024
Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects.
Journal: Journal of hematology & oncology
Published: September 05, 2024
Last Updated: 09/26/2026